Q&A: CDRH's Gutierrez, Mansfield Discuss Ongoing Regulatory Efforts in Personalized Medicine
January 02, 2013
Q&A: CDRH's Gutierrez, Mansfield Discuss Ongoing Regulatory Efforts in Personalized Medicine
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Companion Dx Guidance Nearing Release, FDA's Mansfield Offers Some 'Provisional' Advice
April 13, 2011 / Pharmacogenomics Reporter - New OIVD Director Says FDA May Need To Go Back To 'Square One' on IVDMIA Guidance
August 12, 2009 / Pharmacogenomics Reporter - Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK
May 2, 2012 / Pharmacogenomics Reporter - Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter - Roche Discussing Phase III Study with FDA for Personalized Asthma Drug Lebrikizumab
August 10, 2011 / Pharmacogenomics Reporter